Claims for Patent: 9,359,347

Summary for Patent: 9,359,347

Title:	Inhibitors of Akt/PKB with anti-tumor activity
Abstract:	The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering an effective amount of a compound of formula I to the person or animal.
Inventor(s):	Cheng; Jin Q. (Tampa, FL), Sun; Mei (Tampa, FL), Sebti; Said M. (Tampa, FL)
Assignee:	University of South Florida (Tampa, FL)
Application Number:	13/476,098
Patent Claims:	1. A method for inhibiting the survival or proliferation of a human cancer cell or a malignant human tumor cell or killing a human cancer cell or a malignant human tumor cell having elevated or constitutive Akt activity, said method comprising contacting said human cancer cell or a malignant human tumor cell with an effective amount of a compound of formula I: ##STR00004## wherein X is N; Y is O, NH, or S; R.sup.1 is, independently, --H, --OH, --NH.sub.2, --NO.sub.2, halogen, alkyl optionally substituted with --OH, or alkoxy optionally substituted with --OH; R.sup.2 is --C(O)NH.sub.2 or alkoxy optionally substituted with --OH, halogen, alkyl, or alkoxy; R.sup.3 is --H, --OH, --NH.sub.2, --C(O)NH.sub.2 or alkoxy optionally substituted with --OH, halogen, alkyl, or alkoxy; or a pharmaceutically acceptable salt thereof; or a composition comprising said compound. 2. The method according to claim 1, wherein the cancer cell is a cancer cell of the anus, bile duct, bladder, bone, bone marrow, bowel (including colon and rectum), breast, eye, gall bladder, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, ovary, lung, mesothelioma, neuroendocrine, penis, skin, spinal cord, thyroid, vagina, vulva, uterus, liver, muscle, pancreas, prostate, blood cells (including lymphocytes and other immune system cells), or brain. 3. The method according to claim 1, wherein said cancer cell or a malignant human tumor cell is a cancer cell or a malignant human tumor cell of a malignant tumor of the anus, bile duct, bladder, bone, bone marrow, bowel (including colon and rectum), breast, eye, gall bladder, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, ovary, lung, mesothelioma, neuroendocrine, penis, skin, spinal cord, thyroid, vagina, vulva, uterus, liver, muscle, pancreas, prostate, blood cells, or brain. 4. The method of claim 3, wherein said composition comprises a pharmaceutically acceptable carrier or diluent. 5. The method of claim 3, wherein said composition comprises one or more anti-cancer agents. 6. The method of claim 5, wherein said anti-cancer agent is altretamine, bleomycin, bortezomib (VELCADE), busulphan, calcium folinate, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gefitinih (TRESS A), gemcitabinc, hydroxyurea, idarubicin, ifosfamide imatinib (GLEEVEC), irinotecan, liposomal doxorubicin, lomustine, melphalan, mercaptopurine, methotrexate, ruitomycin, mitoxantrone, oxaliplatin, paclitaxel, pentostatin, procarbazine, raltitrexed, streptozocin, tegafur-uracil, temozolomide, thiotepa, tioguanine/thioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine, melphalan, alemtuzumab, cetuximab (ERBITUX), gemtuzumab, iodine 131 tositumomab, rituximab, or trastuzamab (HERCEPTIN). 7. The method of claim 3, wherein said composition further comprises one or more of a mitotic inhibitor, an alkylating agent, an antimetabolite, a DNA intercalator, a topoisomerase inhibitor, an antiangiogenic agent, or an anti estrogen. 8. The method of claim 1, wherein Y is O. 9. The method of claim 1, wherein each R.sup.1 is independently --OH or --CH.sub.2OH. 10. The method of claim 1, wherein R.sup.2 is --C(O)NH.sub.2. 11. The method of claim 1, wherein the compound is API-1. 12. The method of claim 1, wherein the compound is according to formula (II): ##STR00005## or a pharmaceutically acceptable salt thereof. 13. The method of claim 1, wherein the compound is according to the following formula: ##STR00006## or a pharmaceutically acceptable salt thereof. 14. The method of claim 3, wherein the blood cells are lymphocytes or immune system cells.

Details for Patent 9,359,347

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2027-07-12
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2027-07-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2027-07-12